FDA Approves Genentech's Venclexta Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
February 21, 2026
February 21, 2026
SOUTH SAN FRANCISCO, California, Feb. 21 -- Genentech, a member of Roche Group, issued the following news release on Feb. 19, 2026:
* * *
FDA Approves Genentech's Venclexta(R) Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment
Approval expands Genentech's fixed- . . .
* * *
FDA Approves Genentech's Venclexta(R) Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment
Approval expands Genentech's fixed- . . .